Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in the context of investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for investment actions [1]. - The accuracy and reliability of the information are not guaranteed, and users are cautioned against relying solely on the content provided [1]. Group 2 - The website includes information about cryptocurrencies, CFDs, and other financial instruments, highlighting their complexity and associated high risks [1]. - Users are encouraged to conduct their own research and fully understand the workings and risks of any financial instruments before investing [1].

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Amazon cloud unit flags issues at Bahrain, UAE data centers amid Iran strikes March 2, 20266:48 AM UTCUpdated ago By Reuters Amazon reported some recovery in the UAE but recommended that customers use alternate regions as it investigates "additional connectivity issues and error rates." The company did not confirm or deny, when asked earlier, whether the UAE data center incident was connected ...

Jennifer Lynn Davis, a Director of Bob's Discount Furniture (BOBS +0.00%), reported the indirect sale of 2,917,500 shares of Common Stock at $15.94 per share on Feb. 13, 2026, as detailed in the SEC Form 4 filing. Transaction summaryMetricValueShares sold (indirect)2,917,500Transaction value$46.5MPost-transaction shares (direct)0Post-transaction shares (indirect)95,370,751Transaction value based on SEC Form 4 reported price ($15.94); post-transaction value based on Feb. 13, 2026 market close ($20.08). Key q ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in the context of investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for investment actions [1]. - The accuracy and reliability of the information are not guaranteed, and users are cautioned against relying solely on the content provided [1]. Group 2 - The website includes information about cryptocurrencies, CFDs, and other financial instruments, highlighting their complexity and associated high risks [1]. - Users are encouraged to conduct their own research and fully understand the workings and risks of any financial instruments before investing [1].

Core Viewpoint - Airgain, Inc. and Nextivity, Inc. have entered into a Strategic Partnership Agreement to enhance 4G and 5G coverage solutions in challenging environments [1] Group 1: Partnership Details - The partnership aims to develop integrated solutions for improving wireless connectivity [1] - A structured framework has been established for collaboration between Airgain and Nextivity [1] Group 2: Industry Impact - The collaboration is expected to address challenges in both indoor and outdoor cellular coverage [1] - This partnership positions both companies to leverage their strengths in wireless connectivity and intelligent coverage solutions [1]

Group 1 - The Value Lab focuses on long-only value investment strategies, aiming to identify mispriced international equities with a target portfolio yield of approximately 4% [1][2] - The team has successfully navigated international markets over the past five years, enhancing their global macro commentary and investment insights [1] - The Valkyrie Trading Society, part of The Value Lab, shares high conviction investment ideas that are downside limited and expected to yield non-correlated, outsized returns in the current economic climate [2] Group 2 - The Value Lab provides members with a comprehensive suite of services, including real-time portfolio updates, 24/7 chat support, regular market news reports, and feedback on stock ideas [2] - Monthly new trades and quarterly earnings write-ups are part of the offerings to keep members informed and engaged [2]

Following the escalation of the conflict in the Middle East, energy analysts and investment banks expect oil prices to surge this week to $90 with chances of hitting $100 per barrel if disruptions to traffic in the crucial Strait of Hormuz persist. Early on Monday in Asian trade, oil prices had already spiked by 10% to above $80 per barrel Brent. Seeing the scale of the conflict and the already disrupted traffic through the Strait of Hormuz, analysts expect further spikes at least this week. Citigroup ...

Market Analysis by covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average. Read 's Market Analysis on Investing.com ...

Core Insights - Ericsson and Intel are collaborating to accelerate the transition to AI-native 6G, aiming to make the ecosystem more open, efficient, and cost-effective for operators and the broader industry [1] - The partnership will focus on mobile connectivity, cloud technologies, and compute capabilities, enhancing the deployment of cloud-native solutions [1] - The collaboration is expected to lead to high-performance, energy-efficient compute architectures that support both AI for networks and networks for AI [1] Group 1: Collaboration Details - The collaboration is an extension of a long-standing relationship between Ericsson and Intel, announced at Mobile World Congress Barcelona 2026 [1] - Börje Ekholm, President and CEO of Ericsson, emphasized that 6G will distribute AI across devices, the edge, and the cloud, moving from research to commercial reality [1] - Lip-Bu Tan, CEO of Intel, stated that the goal is to unify RAN, Core, and edge AI for a seamless transition to AI-native 6G environments [1] Group 2: Industry Impact - The industry requires a collaborative ecosystem aligned with global standards to turn innovation into deployable infrastructure as 6G transitions from research to commercial use [1] - AI-native 6G will integrate intelligent and programmable networks with advanced compute and real-time sensing, enhancing service responsiveness and efficiency [1] - Demonstrations of the collaboration's results are being showcased at MWC 2026, highlighting achievements in cloud RAN, 5G Core, and open network infrastructure [1]

Core Insights - Genentech announced that the pivotal Phase III study (FENhance 1) of fenebrutinib in relapsing multiple sclerosis (RMS) met its primary endpoint, showing a 51% reduction in annualized relapse rate (ARR) compared to teriflunomide over at least 96 weeks of treatment [1][3] - The results from FENhance 1 are consistent with FENhance 2, which showed a 59% reduction in ARR, indicating a profound benefit on relapsing and progressive disease biology [1][3] - Secondary endpoints in both RMS studies demonstrated statistically significant reductions in brain lesions, with favorable trends observed in all progression endpoints for fenebrutinib [1][3] Study Details - FENhance 1 and 2 are Phase III multicenter, randomized, double-blind studies involving 1,497 adult patients with RMS, comparing fenebrutinib to teriflunomide [7] - Participants were randomized 1:1 to receive either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks [7] - The primary endpoint was ARR, while secondary endpoints included MRI lesion counts and measures of disability progression [8] Safety and Efficacy - Liver transaminase elevations in both RMS studies were comparable to teriflunomide, with one Hy's Law case reported in each treatment arm, both of which were asymptomatic and resolved after discontinuation [4] - A total of 1 fatal case was reported in the teriflunomide arm, while 8 fatal cases occurred in the fenebrutinib arms, with further analyses ongoing to understand these findings [5] - Fenebrutinib targets B cells and microglia to control acute inflammation and address chronic damage, designed to have high potency and selectivity [6][11][12] Future Developments - Full data from the FENhance 1 and 2 studies will be presented at the American Academy of Neurology (AAN) Annual Meeting in 2026 and submitted to regulatory authorities alongside data from the FENtrepid study [2]